Conformis to Present at Canaccord Genuity and Morgan Stanley Conferences
Bedford, Mass. – March 15, 2013 – Conformis, Inc., a privately held medical device company pioneering patient-specific orthopedic implants, announced today its participation in two upcoming investment conferences:
Canaccord Genuity Musculoskeletal Conference, March 19, 2013,1:10 p.m. CT, The Westin Michigan Avenue, Chicago, Ill. – Dr. Philipp Lang, CEO of Conformis, will present an update on the company and provide an overview of the company’s personalized technology platform, including the iTotal® G2 patient-specific total knee replacement system.
Canaccord Genuity’s Musculoskeletal Conference directly precedes the American Academy of Orthopedic Surgeons Annual Meeting and will explore the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies. This event is expected to have 60 companies present, both public and private, along with a keynote luncheon presentation featuring Canaccord Genuity’s Chief US Equity Strategist, Tony Dwyer.
Morgan Stanley Clinical Debates in Devices Conference, March 28, 2013, 9:30 a.m. ET, Boston Harbor Hotel, Boston, Mass. — Dr. Philipp Lang will participate on a panel exploring customization and robotics in orthopedics. He will discuss the rationale for patient specific implants and Conformis’s approach, business model and personalization trends in the industry.
In Fall 2012, Conformis announced the commercial launch of the iTotal G2, the only patient-specific total knee replacement implant system available on the market. The iTotal allows Conformis to address the largest segment of the knee replacement market, currently a $6 billion dollar category. Conformis also recently moved its corporate office to a new facility in Massachusetts to support the recent and expected forward growth of the company.
About Conformis, Inc.
Conformis, Inc. is a privately-held medical device company that develops and commercializes patient-specific implants and instrumentation to address all stages of osteoarthritis, the most common reason forknee replacement surgery. With more than 350 patents and patent applications spanning knee, hip, shoulder, spine and small joints, Conformis offers a personalized approach over traditional orthopedic implants with their iUni® G2, iDuo® G2 and iTotal® G2. All devices have been cleared by the US Food and Drug Administration for marketing in the US. In 2009, Conformis was named a winner of the Medical Design Excellence Awards for the iUni® and iDuo® resurfacing implants and in 2011, received a Medical Design Excellence Award and an American Technology Award for Innovation for the iTotal® CR Knee Replacement System. Follow @Conformis and become a fan on Facebook.
Conformis Announces Settlement of Patent Dispute with Smith & Nephew
Conformis to Receive $10.5 Million for Non-Exclusive License to Patient-Specific Instrument Patents for use with off-the-shelf knee implants BILLERICA, Mass.,
Conformis announces election of Carrie Bienkowski to its Board of Directors
BILLERICA, Mass., August 2, 2018 (GLOBE NEWSWIRE) – Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit